Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Spruce Biosciences Inc
(NQ:
SPRB
)
0.7480
-0.0020 (-0.27%)
Streaming Delayed Price
Updated: 1:34 PM EDT, May 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Spruce Biosciences Inc
< Previous
1
2
Next >
Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan
January 06, 2023
Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan
January 05, 2023
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
November 10, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in November Investor Conferences
October 26, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in June Investor Conferences
June 01, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
May 31, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in May Investor Conferences
May 03, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer
April 11, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
March 14, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
March 14, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
January 24, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
January 05, 2022
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
November 15, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Mike Grey as Interim CEO
November 15, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in September Investor Conferences
September 07, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
August 25, 2021
From
Spruce Biosciences
Via
Business Wire
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 10, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
June 24, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
June 21, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at 23rd European Congress of Endocrinology
May 24, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences to Participate in the RBC Capital Markets Global Healthcare Conference
May 13, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
Spruce Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 12, 2021
From
Spruce Biosciences, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.